Education
About Us
Working with TipRanks
Follow Us
PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.27
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$10.34M
Enterprise ValueC$11.89M
Total Cash (Recent Filing)C$857.05K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtHaving no debt meaningfully reduces near-term refinancing and interest-rate risk for a small biotech. This conservative capital structure preserves flexibility to fund R&D, support clinical supply obligations, and raise equity on better terms over the next several months if needed, improving survivability during continued development spending.
Top-line MomentumSustained TTM revenue growth (24.6%) indicates improving commercial traction for pharmaceutical-grade MDMA or related services. Durable top-line momentum can strengthen operating leverage over time, support larger-scale clinical supply contracts, and make future partnership or licensing discussions more credible to partners and investors.
Strategic Position In Psychedelic-medicineA clear focus on pharmaceutical-grade MDMA and clinical supply places the company within a structurally growing psychedelic-medicine ecosystem. As regulatory and clinical activity advances, being a specialized supplier to trials and therapy development creates a durable, non-consumer-dependent revenue niche and potential for long-term partnerships.
Bears Say
Negative Gross Profit & Large LossesNegative gross profit indicates the core operations are currently loss-making before overheads, signaling structural margin problems. Persistent operating and net losses erode equity and limit internal funding ability, meaning the company must rely on external capital or partnerships to sustain clinical programs and commercialization efforts.
Cash Burn / Weak Cash GenerationContinued negative operating and free cash flow shows the company is consuming cash to fund operations and development. Over a 2-6 month horizon this raises the probability of near-term financing needs, which could dilute existing shareholders or constrain spending on trials, supply scale-up, and commercialization.
Deteriorating Profitability TrendProfitability worsening versus the prior year suggests rising costs, margin compression, or pricing pressure that are not transitory. If cost structure or pricing dynamics remain adverse, the company may struggle to achieve sustainable margins even as revenue grows, prolonging dependence on external capital and limiting long-term viability.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.27 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$10.34M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is May 04, 2026 which is in 75 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
Sirona Biochem
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---